Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ributable to common shareholders was $0.03 million, or $0.00 per share, compared to $4.3 million, or $0.14 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which resulted in a non-cash decrease of expenses of $2.9 million for the three months ended September 30, 2011 compared to a non-cash decrease of expenses of $0.08 million for the same period in 2010. The decrease in fair value realized during the third quarter of 2011 was primarily the result of the decrease in PharmAthene's stock price from $2.94 per share on June 30, 2011 to $1.76 per share on September 30, 2011.

As of September 30, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $16.9 million compared to $21.6 million at December 31, 2010.  The decrease at September 30, 2011 was primarily due to a combination of a loss from operations of $10.6 million, partially offset by proceeds from a registered direct public offering of common stock and warrants completed in June 2011, which raised net proceeds for the Company of $5.8 million, as well as a net reduction in receivables, prepaid expenses and other current assets and noncash expenses."During the quarter we made significant progress across our biodefense countermeasures programs, particularly in our development of our second generation anthrax vaccine, SparVax™," continued Mr. Richman.  "We recently completed the first 1,500 cGMP manufacturing production run as part of the development of a robust manufacturing process.  This is a significant achievement for our Company and enables us to potentially produce more than 150 million rPA vaccine equivalent doses of bulk drug substance at a 50 mcg dose.  We were also awarded a contract valued at $5.7 million
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Having access to safe ... uphill battle in many corners of the globe. It’s ... community in northwestern Bolivia where many have been sickened ... from Fairfield University’s School of Engineering has been working ... Campesina (UAC), “the united college for the peasants.” A ...
(Date:10/31/2014)... Burlington, MA (PRWEB) October 31, 2014 ... is hosting a free learning webinar to introduce its ... managers, standards directors and biostatisticians. , Launched in September, ... the company's suite of clinical trial automation tools. For ... in a web browser. And by introducing Formations – ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Stronger ... healthcare, construction, finance and consumer electronics will help ... reason, industry research firm IBISWorld has added a ... its growing industry report collection. , The Biometrics ... for biometric technologies such as fingerprint, iris, retina ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Fairfield University School of Engineering project reduces illness in rural community 2Fairfield University School of Engineering project reduces illness in rural community 3Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 2Biometrics Scan Software in the US Industry Market Research Report Now Available from IBISWorld 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ), ... Western healthcare products in the People,s,Republic of China, ... fourth quarter which will be reported in the ... filed with the Securities and Exchange Commission,on Monday, ...
... XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today ... and Extraordinary General,Meeting (collectively, the "Meetings") scheduled for July ... at the close of business on,June 12, 2008 are ... Meetings. All,shareholders are cordially invited to attend the Meetings ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY), announced today that ... in two separate presentations at the,BIO 2008 International Convention., ... overview of the,Company on Tuesday, June 17th at 3:30 ... Wednesday, June 18th at 4:00 p.m. PT, Dr. Thompson ...
Cached Biology Technology:Chindex International, Inc. Quantifies Fourth Quarter Charges 2Chindex International, Inc. Quantifies Fourth Quarter Charges 3Notification of Record Date for the Annual General Meeting and Extraordinary General Meeting 2Oncolytics Biotech Inc. to Present at BIO 2008 International Convention 2
(Date:10/29/2014)... lose their hair as a consequence of chemotherapy will ... the scalp cooling technology that prevents hair loss. , ... pioneered by global scalp cooling manufacturing company, Paxman Coolers, ... department of the University of Huddersfield. , The research ... has a background in the pharmacology of cancer treatment, ...
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... of chemicals from household and industrial products are in ... But for most of them, scientists have yet to ... the first step toward doing that by estimating which ... method is published in the ACS journal Environmental ... colleagues note that the risks to human health of ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... in Proceedings of the National Academy of Sciences, USA, ... the genomics of primitive living fishes such as sharks ... sea squirts. Vertebrates - animals such as ... anatomically and genetically complex of all organisms, but explaining ...
... 11, 2008) Researchers at the Georgia Institute of ... eventually recycle carbon from vehicles to prevent the pollutant ... the atmosphere. Georgia Tech researchers envision a zero emission ... fuels. Technologies to capture carbon dioxide emissions from ...
... Ill. --- In the science world, in the media, ... over how carbon in the atmosphere is affecting global ... Earth is an enormous challenge, but one Northwestern University ... segment -- rivers. Aaron Packman, associate professor of ...
Cached Biology News:Carbon capture strategy could lead to emission-free cars 2Carbon capture strategy could lead to emission-free cars 3Carbon capture strategy could lead to emission-free cars 4Studying rivers for clues to global carbon cycle 2Studying rivers for clues to global carbon cycle 3
Kit containing MACS equipment and reagents for immunopurification of proteins....
... biomarker discovery projects require screening through ... distinguish clinically relevant data from normal ... Manager is now available to help ... and data flood inherent to biomarker ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
Biology Products: